Skip to content

Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia. A randomized phase III study conducted in agreement with the AIEOP-BFM study group.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-517253-27-00
Acronym
AIEOP-BFM 2017POLAND
Enrollment
874
Registered
2024-10-28
Start date
2021-07-01
Completion date
Unknown
Last updated
2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute lymphoblastic leukemia

Brief summary

R-eHR: The primary endpoint will be the time from randomization until the first event defined as follows: • Cytomorphological or molecular non-response (resistance to protocol treatment, considered as event after post-consolidation treatment – HR blocks or blinatumomab therapy), • relapse, • second malignancy or death from any cause. This will be called EFS time., (2a) R-HR: Frequency and incidence of grade 4 adverse events or death from any cause, non-serious adverse events of medical interest during post-consolidation treatment (blinatumomab and HR blocks), (2a) R-HR: Frequency of MRD-negative patients after first and third cycle of Blinatumomab or after the HR-1’/HR-3’ block compared under non-inferiority assumption

Detailed description

(1b) Time from randomization to death from any cause, (1c) Frequency and incidence of grade 4 adverse events or death during Consol Bext and after but before 1st day of HR-1` block or 1st blinatumomab cycle., (1c, 2a) Frequency and incidence of AE of special interest and SAE in specific protocol phases, randomized arms and overall during follow-up, (1d) Proportion of children with negative MRD at TP1a and TP2, (2b) Absolute difference in MRD load between TP2 and TP after first blinatumomab cycle or HR-1, (2b) Absolute difference in MRD load between TP2 and third Blinatumomab cycle or HR-3`, (2c) Absolute MRD loads at TP2 and TP HR Blina 1, d29 71, 113 and TP2, TP HR1, TP HR2, TP HR3., (2d) Time from the first day of first Blinatumomab cycle or HR-1` block to event: death from any cause (for OS), death, relapse, secondary malignancy or molecular non-response for EFS)., (1e, 2f) R-eHR, R-HR: appropriately-defined times to events, frequencies of grade 4 adverse events or death and proportion of patients achieving negative MRD at corresponding timepoints.

Interventions

DRUGBLINATUMOMAB
DRUGBORTEZOMIB
DRUGPREDNISONE
DRUGIFOSFAMIDE
DRUGETOPOSIDE
DRUGPREDNISOLONE
DRUGDEXAMETHASONE
DRUGCYCLOPHOSPHAMIDE
DRUGMETHOTREXATE
DRUGVINCRISTINE SULFATE
DRUGDOXORUBICIN HYDROCHLORIDE
DRUGDEXAMETHASONE PHOSPHATE
DRUGCYTARABINE
DRUGPEGASPARGASE
DRUGMERCAPTOPURINE
DRUGDAUNORUBICIN HYDROCHLORIDE
DRUGFLUDARABINE PHOSPHATE

Sponsors

Medical University Of Silesia Katowice Poland
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
0 Years to 17 Years

Design outcomes

Primary

MeasureTime frame
R-eHR: The primary endpoint will be the time from randomization until the first event defined as follows: • Cytomorphological or molecular non-response (resistance to protocol treatment, considered as event after post-consolidation treatment – HR blocks or blinatumomab therapy), • relapse, • second malignancy or death from any cause. This will be called EFS time., (2a) R-HR: Frequency and incidence of grade 4 adverse events or death from any cause, non-serious adverse events of medical interest during post-consolidation treatment (blinatumomab and HR blocks), (2a) R-HR: Frequency of MRD-negative patients after first and third cycle of Blinatumomab or after the HR-1’/HR-3’ block compared under non-inferiority assumption

Secondary

MeasureTime frame
(1b) Time from randomization to death from any cause, (1c) Frequency and incidence of grade 4 adverse events or death during Consol Bext and after but before 1st day of HR-1` block or 1st blinatumomab cycle., (1c, 2a) Frequency and incidence of AE of special interest and SAE in specific protocol phases, randomized arms and overall during follow-up, (1d) Proportion of children with negative MRD at TP1a and TP2, (2b) Absolute difference in MRD load between TP2 and TP after first blinatumomab cycle or HR-1, (2b) Absolute difference in MRD load between TP2 and third Blinatumomab cycle or HR-3`, (2c) Absolute MRD loads at TP2 and TP HR Blina 1, d29 71, 113 and TP2, TP HR1, TP HR2, TP HR3., (2d) Time from the first day of first Blinatumomab cycle or HR-1` block to event: death from any cause (for OS), death, relapse, secondary malignancy or molecular non-response for EFS)., (1e, 2f) R-eHR, R-HR: appropriately-defined times to events, frequencies of grade 4 adverse events or death and proport

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026